Related Experiment Videos
Growth retardation and tumour inhibition by BRCA1
J T Holt1, M E Thompson, C Szabo
1Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2175, USA.
Abstract:
Inherited mutations in BRCA1 predispose to breast and ovarian cancer, but the role of BRCA1 in sporadic breast and ovarian cancer has previously been elusive. Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts. Mutant BRCA1 has no effect on growth of breast cancer cells; ovarian cancer cell growth is not affected by BRCA1 mutations in the 5' portion of the gene, but is inhibited by 3' BRCA1 mutations. Development of MCF-7 tumours in nude mice is inhibited when MCF-7 cells are transfected with wild-type, but not mutant, BRCA1. Most importantly, among mice with established MCF-7 tumours, peritoneal treatment with a retroviral vector expressing wild-type BRCA1 significantly inhibits tumour growth and increased survival.
Insights
Restoring wild-type BRCA1 gene function suppressed breast and ovarian cancer cell growth. This gene therapy approach also inhibited tumor development and improved survival in mice, offering potential for new cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- The role of BRCA1 in sporadic breast and ovarian cancers remained unclear despite its known link to inherited forms.
- BRCA1 gene mutations are associated with increased risk for hereditary breast and ovarian cancers.
Purpose of the Study:
- To investigate the therapeutic potential of wild-type BRCA1 gene transfer in sporadic breast and ovarian cancers.
- To determine the effect of wild-type and mutant BRCA1 on cancer cell proliferation and tumor development.
Main Methods:
- Retroviral gene transfer of wild-type and mutant BRCA1 into various cancer cell lines (breast, ovarian, colon, lung) and fibroblasts.
- In vitro cell growth assays and in vivo tumor development studies in nude mice using MCF-7 breast cancer cells.
- Evaluation of tumor growth inhibition and survival rates in mice treated with retroviral BRCA1 vectors.
Main Results:
- Wild-type BRCA1 gene transfer inhibited in vitro growth of breast and ovarian cancer cell lines, but not colon or lung cancer cells or fibroblasts.
- Mutant BRCA1 did not affect breast cancer cell growth; its effect on ovarian cancer cells varied based on mutation location (5' vs. 3').
- In vivo studies demonstrated that wild-type BRCA1 transfection inhibited MCF-7 tumor development in mice, and retroviral treatment of established tumors significantly reduced growth and increased survival.
Conclusions:
- Wild-type BRCA1 exhibits tumor-suppressive activity in sporadic breast and ovarian cancers.
- Retroviral delivery of wild-type BRCA1 holds promise as a therapeutic strategy for inhibiting cancer progression and improving outcomes.
- The location of BRCA1 mutations influences their impact on ovarian cancer cell growth.